Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial is a research paper published in PLoS ONE (2022). On theSindex it has a DataRank of 0.577. It has been cited 13 times, with 9 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.396
From this paper's citation signal
Citation Network Contribution
0.181
From 7 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 9 citers.
National Heart, Lung, and Blood Institute
Grant: 1K12HL138049-01
K12 Cardiopulmonary Implementation Science Scholars Program
NCATS NIH HHS
Grant: UL1 TR001863
NHLBI NIH HHS
Grant: K12 HL138049
FWCI
1.26
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals